DUPONT CAPITAL MANAGEMENT CORP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 335 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.

Quarter-by-quarter ownership
DUPONT CAPITAL MANAGEMENT CORP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$79,426
-15.2%
2,202
-10.2%
0.00%0.0%
Q1 2023$93,680
-84.5%
2,453
-77.0%
0.00%
-86.2%
Q4 2022$605,644
+49.2%
10,644
+3.7%
0.03%
+20.8%
Q3 2022$406,000
-32.4%
10,262
-24.8%
0.02%
-14.3%
Q2 2022$601,000
+144.3%
13,648
+121.5%
0.03%
+180.0%
Q1 2022$246,000
-50.1%
6,162
-49.7%
0.01%
-44.4%
Q4 2021$493,000
-29.2%
12,259
-28.4%
0.02%
-18.2%
Q3 2021$696,000
-17.7%
17,113
-8.1%
0.02%
+10.0%
Q2 2021$846,000
-48.1%
18,629
-52.3%
0.02%
-48.7%
Q1 2021$1,629,000
+11.0%
39,066
+13.7%
0.04%
+25.8%
Q4 2020$1,468,000
+118.8%
34,364
+34.7%
0.03%
+106.7%
Q3 2020$671,000
-33.4%
25,518
-32.0%
0.02%
-31.8%
Q2 2020$1,007,000
+36.8%
37,551
-8.2%
0.02%
+22.2%
Q1 2020$736,000
+1.5%
40,9040.0%0.02%
+12.5%
Q4 2019$725,000
-25.9%
40,904
-15.3%
0.02%
-27.3%
Q4 2017$978,000
+16.7%
48,2700.0%0.02%
+15.8%
Q3 2017$838,000
+233.9%
48,270
+147.0%
0.02%
+216.7%
Q2 2017$251,000
-0.8%
19,5430.0%0.01%0.0%
Q1 2017$253,000
-43.5%
19,543
-56.9%
0.01%
-40.0%
Q4 2016$448,00045,3310.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Third Security, LLC 7,048,282$126,799,00027.23%
First Light Asset Management, LLC 1,630,591$29,334,0005.01%
SNYDER CAPITAL MANAGEMENT L P 3,393,057$61,041,0003.48%
Bellevue Group AG 7,663,956$137,874,0002.67%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 307,633$5,531,0002.52%
Lombard Odier Asset Management (Switzerland) SA 900,000$16,191,0002.17%
Elk Creek Partners, LLC 654,362$11,772,0002.02%
DOHENY ASSET MANAGEMENT /CA 127,110$2,254,0001.79%
Granite Investment Partners, LLC 1,277,438$22,981,0001.49%
Amia Capital LLP 69,409$1,249,0001.11%
View complete list of HALOZYME THERAPEUTICS INC shareholders